WALDENSTROM'S MACROGLOBULINAEMIA REFRACTORY

Clinical trials for WALDENSTROM'S MACROGLOBULINAEMIA REFRACTORY explained in plain language.

Never miss a new study

Get alerted when new WALDENSTROM'S MACROGLOBULINAEMIA REFRACTORY trials appear

Sign up with your email to follow new studies for WALDENSTROM'S MACROGLOBULINAEMIA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Can a radioactive drug outperform standard therapy in waldenstrom macroglobulinemia?

Disease control Not yet recruiting

This phase 3 trial is testing whether a radioactive drug called iopofosine I 131 can keep Waldenstrom macroglobulinemia (a rare blood cancer) from getting worse for longer than the standard combination of rituximab, cyclophosphamide, and dexamethasone (R-CD). The study enrolls ab…

Matched conditions: WALDENSTROM'S MACROGLOBULINAEMIA REFRACTORY

Phase: PHASE3 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control

Last updated Aug 16, 2026 00:00 UTC

WALDENSTROM'S MACROGLOBULINAEMIA REFRACTORY

Get alerted when new WALDENSTROM'S MACROGLOBULINAEMIA REFRACTORY trials appear

Can a radioactive drug outperform standard therapy in waldenstrom macroglobulinemia?